Health Catalyst, Inc. (NASDAQ: HCAT) Stock Competitors & Peer Comparison
See HCAT's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for HCAT and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HCAT | $2.25 | -1.32% | 166.3M | 11.25 | $0.20 | N/A |
| VEEV | $195.38 | -1.01% | 31.7B | 23.46 | $8.33 | N/A |
| GEHC | $63.07 | -4.00% | 28.7B | 13.83 | $4.56 | +0.22% |
| GEHCV | $56.00 | -4.08% | 25.5B | N/A | N/A | N/A |
| BTSG | $70.69 | +3.71% | 13.9B | 57.01 | $1.24 | N/A |
| BTSGU | $231.53 | +1.23% | 13.5B | 209.36 | $1.11 | N/A |
| TEM | $52.47 | -2.09% | 9.2B | -104.94 | -$0.50 | N/A |
| SGFY | $30.49 | +0.07% | 8.9B | 70.91 | $0.43 | N/A |
| HQY | $97.67 | +2.73% | 8.3B | 23.06 | $4.28 | N/A |
| HNGE | $87.09 | +1.29% | 6.7B | 44.66 | $1.95 | N/A |
Stock Comparison
Veeva Systems Inc. (NYSE: VEEV)
HCAT vs VEEV Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, VEEV has a market cap of 31.7B. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while VEEV trades at $195.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas VEEV's P/E ratio is 23.46. In terms of profitability, HCAT's ROE is -1.00%, compared to VEEV's ROE of +0.13%. Regarding short-term risk, HCAT is more volatile compared to VEEV. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check VEEV's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
HCAT vs GEHC Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, GEHC has a market cap of 28.7B. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while GEHC trades at $63.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas GEHC's P/E ratio is 13.83. In terms of profitability, HCAT's ROE is -1.00%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, HCAT is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check GEHC's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHCV)
HCAT vs GEHCV Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while GEHCV trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas GEHCV's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to GEHCV's ROE of +0.19%. Regarding short-term risk, HCAT is less volatile compared to GEHCV. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check GEHCV's competition here
BrightSpring Health Services, Inc. Common Stock (NASDAQ: BTSG)
HCAT vs BTSG Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, BTSG has a market cap of 13.9B. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while BTSG trades at $70.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas BTSG's P/E ratio is 57.01. In terms of profitability, HCAT's ROE is -1.00%, compared to BTSG's ROE of +0.17%. Regarding short-term risk, HCAT is less volatile compared to BTSG. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check BTSG's competition here
BrightSpring Health Services, Inc. Tangible Equity Unit (NASDAQ: BTSGU)
HCAT vs BTSGU Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, BTSGU has a market cap of 13.5B. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while BTSGU trades at $231.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas BTSGU's P/E ratio is 209.36. In terms of profitability, HCAT's ROE is -1.00%, compared to BTSGU's ROE of +0.17%. Regarding short-term risk, HCAT is more volatile compared to BTSGU. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check BTSGU's competition here
Tempus AI, Inc. (NASDAQ: TEM)
HCAT vs TEM Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, TEM has a market cap of 9.2B. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while TEM trades at $52.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas TEM's P/E ratio is -104.94. In terms of profitability, HCAT's ROE is -1.00%, compared to TEM's ROE of -0.70%. Regarding short-term risk, HCAT is more volatile compared to TEM. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check TEM's competition here
Signify Health, Inc. (NYSE: SGFY)
HCAT vs SGFY Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while SGFY trades at $30.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas SGFY's P/E ratio is 70.91. In terms of profitability, HCAT's ROE is -1.00%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, HCAT is more volatile compared to SGFY. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check SGFY's competition here
HealthEquity, Inc. (NASDAQ: HQY)
HCAT vs HQY Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, HQY has a market cap of 8.3B. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while HQY trades at $97.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas HQY's P/E ratio is 23.06. In terms of profitability, HCAT's ROE is -1.00%, compared to HQY's ROE of +0.11%. Regarding short-term risk, HCAT is more volatile compared to HQY. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check HQY's competition here
Hinge Health, Inc. (NYSE: HNGE)
HCAT vs HNGE Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, HNGE has a market cap of 6.7B. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while HNGE trades at $87.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas HNGE's P/E ratio is 44.66. In terms of profitability, HCAT's ROE is -1.00%, compared to HNGE's ROE of -1.39%. Regarding short-term risk, HCAT is more volatile compared to HNGE. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check HNGE's competition here
R1 RCM Inc. (NASDAQ: RCM)
HCAT vs RCM Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, RCM has a market cap of 6B. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while RCM trades at $14.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas RCM's P/E ratio is -102.21. In terms of profitability, HCAT's ROE is -1.00%, compared to RCM's ROE of +0.00%. Regarding short-term risk, HCAT is more volatile compared to RCM. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check RCM's competition here
10x Genomics, Inc. (NASDAQ: TXG)
HCAT vs TXG Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, TXG has a market cap of 5.6B. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while TXG trades at $43.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas TXG's P/E ratio is -257.29. In terms of profitability, HCAT's ROE is -1.00%, compared to TXG's ROE of -0.03%. Regarding short-term risk, HCAT is more volatile compared to TXG. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check TXG's competition here
Doximity, Inc. (NYSE: DOCS)
HCAT vs DOCS Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, DOCS has a market cap of 4B. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while DOCS trades at $21.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas DOCS's P/E ratio is 14.07. In terms of profitability, HCAT's ROE is -1.00%, compared to DOCS's ROE of +0.19%. Regarding short-term risk, HCAT is more volatile compared to DOCS. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check DOCS's competition here
1Life Healthcare, Inc. (NASDAQ: ONEM)
HCAT vs ONEM Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while ONEM trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas ONEM's P/E ratio is -7.77. In terms of profitability, HCAT's ROE is -1.00%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, HCAT is more volatile compared to ONEM. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check ONEM's competition here
Privia Health Group, Inc. (NASDAQ: PRVA)
HCAT vs PRVA Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, PRVA has a market cap of 3.4B. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while PRVA trades at $26.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas PRVA's P/E ratio is 168.13. In terms of profitability, HCAT's ROE is -1.00%, compared to PRVA's ROE of +0.03%. Regarding short-term risk, HCAT is more volatile compared to PRVA. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check PRVA's competition here
Progyny, Inc. (NASDAQ: PGNY)
HCAT vs PGNY Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, PGNY has a market cap of 2.5B. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while PGNY trades at $31.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas PGNY's P/E ratio is 23.31. In terms of profitability, HCAT's ROE is -1.00%, compared to PGNY's ROE of +0.13%. Regarding short-term risk, HCAT is more volatile compared to PGNY. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check PGNY's competition here
Heartflow, Inc. Common Stock (NASDAQ: HTFL)
HCAT vs HTFL Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, HTFL has a market cap of 2.2B. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while HTFL trades at $24.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas HTFL's P/E ratio is -12.92. In terms of profitability, HCAT's ROE is -1.00%, compared to HTFL's ROE of +8.30%. Regarding short-term risk, HCAT is more volatile compared to HTFL. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check HTFL's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
HCAT vs WGS Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, WGS has a market cap of 1.9B. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while WGS trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas WGS's P/E ratio is 74.68. In terms of profitability, HCAT's ROE is -1.00%, compared to WGS's ROE of -0.28%. Regarding short-term risk, HCAT is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check WGS's competition here
Teladoc Health, Inc. (NYSE: TDOC)
HCAT vs TDOC Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, TDOC has a market cap of 1.7B. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while TDOC trades at $9.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas TDOC's P/E ratio is -10.47. In terms of profitability, HCAT's ROE is -1.00%, compared to TDOC's ROE of -0.12%. Regarding short-term risk, HCAT is more volatile compared to TDOC. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check TDOC's competition here
NextGen Healthcare, Inc. (NASDAQ: NXGN)
HCAT vs NXGN Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while NXGN trades at $23.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas NXGN's P/E ratio is -266.00. In terms of profitability, HCAT's ROE is -1.00%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, HCAT is more volatile compared to NXGN. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check NXGN's competition here
Omada Health (NASDAQ: OMDA)
HCAT vs OMDA Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, OMDA has a market cap of 1.4B. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while OMDA trades at $23.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas OMDA's P/E ratio is 338.57. In terms of profitability, HCAT's ROE is -1.00%, compared to OMDA's ROE of -0.03%. Regarding short-term risk, HCAT is more volatile compared to OMDA. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check OMDA's competition here
Agiliti, Inc. (NYSE: AGTI)
HCAT vs AGTI Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while AGTI trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas AGTI's P/E ratio is -71.79. In terms of profitability, HCAT's ROE is -1.00%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, HCAT is more volatile compared to AGTI. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check AGTI's competition here
GoodRx Holdings, Inc. (NASDAQ: GDRX)
HCAT vs GDRX Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, GDRX has a market cap of 1.1B. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while GDRX trades at $3.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas GDRX's P/E ratio is 9.52. In terms of profitability, HCAT's ROE is -1.00%, compared to GDRX's ROE of +0.03%. Regarding short-term risk, HCAT is more volatile compared to GDRX. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check GDRX's competition here
Certara, Inc. (NASDAQ: CERT)
HCAT vs CERT Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, CERT has a market cap of 1.1B. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while CERT trades at $6.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas CERT's P/E ratio is 17.77. In terms of profitability, HCAT's ROE is -1.00%, compared to CERT's ROE of -0.01%. Regarding short-term risk, HCAT is less volatile compared to CERT. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check CERT's competition here
CareCloud, Inc. (NASDAQ: CCLDO)
HCAT vs CCLDO Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, CCLDO has a market cap of 857.3M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while CCLDO trades at $27.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas CCLDO's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to CCLDO's ROE of +0.17%. Regarding short-term risk, HCAT is more volatile compared to CCLDO. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check CCLDO's competition here
HealthStream, Inc. (NASDAQ: HSTM)
HCAT vs HSTM Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, HSTM has a market cap of 845.5M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while HSTM trades at $28.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas HSTM's P/E ratio is 38.08. In terms of profitability, HCAT's ROE is -1.00%, compared to HSTM's ROE of +0.06%. Regarding short-term risk, HCAT is more volatile compared to HSTM. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check HSTM's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
HCAT vs WGSWW Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, WGSWW has a market cap of 748M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas WGSWW's P/E ratio is -0.02. In terms of profitability, HCAT's ROE is -1.00%, compared to WGSWW's ROE of -0.28%. Regarding short-term risk, HCAT is less volatile compared to WGSWW. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check WGSWW's competition here
Phreesia, Inc. (NYSE: PHR)
HCAT vs PHR Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, PHR has a market cap of 662M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while PHR trades at $10.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas PHR's P/E ratio is 38.25. In terms of profitability, HCAT's ROE is -1.00%, compared to PHR's ROE of +0.03%. Regarding short-term risk, HCAT is more volatile compared to PHR. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check PHR's competition here
Evolent Health, Inc. (NYSE: EVH)
HCAT vs EVH Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, EVH has a market cap of 652.4M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while EVH trades at $5.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas EVH's P/E ratio is 580.00. In terms of profitability, HCAT's ROE is -1.00%, compared to EVH's ROE of -0.78%. Regarding short-term risk, HCAT is more volatile compared to EVH. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check EVH's competition here
MultiPlan Corporation (NYSE: MPLN-WT)
HCAT vs MPLN-WT Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while MPLN-WT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to MPLN-WT's ROE of +2.06%. Regarding short-term risk, HCAT is less volatile compared to MPLN-WT. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check MPLN-WT's competition here
Accolade, Inc. (NASDAQ: ACCD)
HCAT vs ACCD Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while ACCD trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas ACCD's P/E ratio is -3.08. In terms of profitability, HCAT's ROE is -1.00%, compared to ACCD's ROE of -0.22%. Regarding short-term risk, HCAT is more volatile compared to ACCD. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check ACCD's competition here
Sharecare, Inc. (NASDAQ: SHCR)
HCAT vs SHCR Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while SHCR trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas SHCR's P/E ratio is -3.76. In terms of profitability, HCAT's ROE is -1.00%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, HCAT is more volatile compared to SHCR. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check SHCR's competition here
Claritev Corporation (NYSE: CTEV)
HCAT vs CTEV Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, CTEV has a market cap of 517.5M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while CTEV trades at $30.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas CTEV's P/E ratio is -2.33. In terms of profitability, HCAT's ROE is -1.00%, compared to CTEV's ROE of +2.06%. Regarding short-term risk, HCAT is more volatile compared to CTEV. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check CTEV's competition here
NRC Health (NASDAQ: NRC)
HCAT vs NRC Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, NRC has a market cap of 490.8M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while NRC trades at $21.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas NRC's P/E ratio is 26.56. In terms of profitability, HCAT's ROE is -1.00%, compared to NRC's ROE of +0.57%. Regarding short-term risk, HCAT is more volatile compared to NRC. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check NRC's competition here
SOPHiA GENETICS S.A. (NASDAQ: SOPH)
HCAT vs SOPH Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, SOPH has a market cap of 403.5M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while SOPH trades at $5.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas SOPH's P/E ratio is -11.29. In terms of profitability, HCAT's ROE is -1.00%, compared to SOPH's ROE of -1.41%. Regarding short-term risk, HCAT is less volatile compared to SOPH. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check SOPH's competition here
SomaLogic, Inc. (NASDAQ: SLGC)
HCAT vs SLGC Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while SLGC trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas SLGC's P/E ratio is -3.04. In terms of profitability, HCAT's ROE is -1.00%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, HCAT is less volatile compared to SLGC. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check SLGC's competition here
SomaLogic, Inc. (NASDAQ: SLGCW)
HCAT vs SLGCW Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while SLGCW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, HCAT's ROE is -1.00%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, HCAT is less volatile compared to SLGCW. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check SLGCW's competition here
TruBridge, Inc. (NASDAQ: TBRG)
HCAT vs TBRG Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, TBRG has a market cap of 393.6M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while TBRG trades at $26.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas TBRG's P/E ratio is 9.37. In terms of profitability, HCAT's ROE is -1.00%, compared to TBRG's ROE of +0.02%. Regarding short-term risk, HCAT is more volatile compared to TBRG. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check TBRG's competition here
MultiPlan Corporation (NYSE: MPLN)
HCAT vs MPLN Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while MPLN trades at $23.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas MPLN's P/E ratio is -0.23. In terms of profitability, HCAT's ROE is -1.00%, compared to MPLN's ROE of +2.06%. Regarding short-term risk, HCAT is less volatile compared to MPLN. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check MPLN's competition here
Simulations Plus, Inc. (NASDAQ: SLP)
HCAT vs SLP Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, SLP has a market cap of 368.7M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while SLP trades at $18.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas SLP's P/E ratio is 20.72. In terms of profitability, HCAT's ROE is -1.00%, compared to SLP's ROE of +0.06%. Regarding short-term risk, HCAT is more volatile compared to SLP. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check SLP's competition here
Tabula Rasa HealthCare, Inc. (NASDAQ: TRHC)
HCAT vs TRHC Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while TRHC trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas TRHC's P/E ratio is -4.27. In terms of profitability, HCAT's ROE is -1.00%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, HCAT is more volatile compared to TRHC. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check TRHC's competition here
Sema4 Holdings Corp. (NASDAQ: SMFR)
HCAT vs SMFR Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while SMFR trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas SMFR's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to SMFR's ROE of -0.28%. Regarding short-term risk, HCAT is less volatile compared to SMFR. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check SMFR's competition here
Spok Holdings, Inc. (NASDAQ: SPOK)
HCAT vs SPOK Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, SPOK has a market cap of 222.2M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while SPOK trades at $10.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas SPOK's P/E ratio is 17.73. In terms of profitability, HCAT's ROE is -1.00%, compared to SPOK's ROE of +0.09%. Regarding short-term risk, HCAT is more volatile compared to SPOK. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check SPOK's competition here
So-Young International Inc. (NASDAQ: SY)
HCAT vs SY Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, SY has a market cap of 220.4M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while SY trades at $1.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas SY's P/E ratio is -5.09. In terms of profitability, HCAT's ROE is -1.00%, compared to SY's ROE of -0.16%. Regarding short-term risk, HCAT is more volatile compared to SY. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check SY's competition here
American Well Corporation (NYSE: AMWL)
HCAT vs AMWL Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, AMWL has a market cap of 220.3M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while AMWL trades at $13.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas AMWL's P/E ratio is -2.54. In terms of profitability, HCAT's ROE is -1.00%, compared to AMWL's ROE of -0.35%. Regarding short-term risk, HCAT is less volatile compared to AMWL. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check AMWL's competition here
Computer Programs and Systems, Inc. (NASDAQ: CPSI)
HCAT vs CPSI Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while CPSI trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas CPSI's P/E ratio is -183.80. In terms of profitability, HCAT's ROE is -1.00%, compared to CPSI's ROE of +0.02%. Regarding short-term risk, HCAT is less volatile compared to CPSI. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check CPSI's competition here
OptimizeRx Corp. (NASDAQ: OPRX)
HCAT vs OPRX Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, OPRX has a market cap of 125.5M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while OPRX trades at $6.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas OPRX's P/E ratio is 6.14. In terms of profitability, HCAT's ROE is -1.00%, compared to OPRX's ROE of +0.05%. Regarding short-term risk, HCAT is more volatile compared to OPRX. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check OPRX's competition here
Augmedix, Inc. (NASDAQ: AUGX)
HCAT vs AUGX Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while AUGX trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas AUGX's P/E ratio is -4.99. In terms of profitability, HCAT's ROE is -1.00%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, HCAT is more volatile compared to AUGX. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check AUGX's competition here
CareCloud, Inc. (NASDAQ: CCLD)
HCAT vs CCLD Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, CCLD has a market cap of 98.6M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while CCLD trades at $2.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas CCLD's P/E ratio is 8.59. In terms of profitability, HCAT's ROE is -1.00%, compared to CCLD's ROE of +0.17%. Regarding short-term risk, HCAT is more volatile compared to CCLD. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check CCLD's competition here
Definitive Healthcare Corp. (NASDAQ: DH)
HCAT vs DH Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, DH has a market cap of 80.1M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while DH trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas DH's P/E ratio is 2.92. In terms of profitability, HCAT's ROE is -1.00%, compared to DH's ROE of -0.67%. Regarding short-term risk, HCAT is less volatile compared to DH. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check DH's competition here
Forian Inc. (NASDAQ: FORA)
HCAT vs FORA Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, FORA has a market cap of 67.8M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while FORA trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas FORA's P/E ratio is -24.11. In terms of profitability, HCAT's ROE is -1.00%, compared to FORA's ROE of -0.17%. Regarding short-term risk, HCAT is more volatile compared to FORA. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check FORA's competition here
CareCloud, Inc. (NASDAQ: CCLDP)
HCAT vs CCLDP Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while CCLDP trades at $19.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas CCLDP's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to CCLDP's ROE of +0.17%. Regarding short-term risk, HCAT is more volatile compared to CCLDP. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check CCLDP's competition here
OneMedNet Corporation (NASDAQ: ONMD)
HCAT vs ONMD Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, ONMD has a market cap of 38.7M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while ONMD trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas ONMD's P/E ratio is -4.53. In terms of profitability, HCAT's ROE is -1.00%, compared to ONMD's ROE of +0.90%. Regarding short-term risk, HCAT is less volatile compared to ONMD. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check ONMD's competition here
Science 37 Holdings, Inc. (NASDAQ: SNCE)
HCAT vs SNCE Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while SNCE trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas SNCE's P/E ratio is -0.27. In terms of profitability, HCAT's ROE is -1.00%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, HCAT is more volatile compared to SNCE. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check SNCE's competition here
Akili, Inc. (NASDAQ: AKLI)
HCAT vs AKLI Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while AKLI trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas AKLI's P/E ratio is -0.71. In terms of profitability, HCAT's ROE is -1.00%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, HCAT is more volatile compared to AKLI. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check AKLI's competition here
SHL Telemedicine Ltd. (NASDAQ: SHLT)
HCAT vs SHLT Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while SHLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas SHLT's P/E ratio is -3.87. In terms of profitability, HCAT's ROE is -1.00%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, HCAT is more volatile compared to SHLT. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check SHLT's competition here
Sharecare, Inc. (NASDAQ: SHCRW)
HCAT vs SHCRW Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while SHCRW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, HCAT's ROE is -1.00%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, HCAT is more volatile compared to SHCRW. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check SHCRW's competition here
OneMedNet Corporation (NASDAQ: ONMDW)
HCAT vs ONMDW Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, ONMDW has a market cap of 27.7M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while ONMDW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas ONMDW's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to ONMDW's ROE of +0.90%. Regarding short-term risk, HCAT is more volatile compared to ONMDW. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check ONMDW's competition here
Streamline Health Solutions, Inc. (NASDAQ: STRM)
HCAT vs STRM Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while STRM trades at $5.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas STRM's P/E ratio is -2.40. In terms of profitability, HCAT's ROE is -1.00%, compared to STRM's ROE of -0.32%. Regarding short-term risk, HCAT is more volatile compared to STRM. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check STRM's competition here
Renalytix Plc (NASDAQ: RNLX)
HCAT vs RNLX Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while RNLX trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas RNLX's P/E ratio is -0.33. In terms of profitability, HCAT's ROE is -1.00%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, HCAT is less volatile compared to RNLX. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check RNLX's competition here
MSP Recovery, Inc. (NASDAQ: LIFW)
HCAT vs LIFW Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while LIFW trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas LIFW's P/E ratio is -0.02. In terms of profitability, HCAT's ROE is -1.00%, compared to LIFW's ROE of +1.56%. Regarding short-term risk, HCAT is more volatile compared to LIFW. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check LIFW's competition here
EUDA Health Holdings Limited (NASDAQ: EUDA)
HCAT vs EUDA Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, EUDA has a market cap of 21.1M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while EUDA trades at $11.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas EUDA's P/E ratio is -21.32. In terms of profitability, HCAT's ROE is -1.00%, compared to EUDA's ROE of +0.70%. Regarding short-term risk, HCAT is more volatile compared to EUDA. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check EUDA's competition here
Babylon Holdings Limited (NYSE: BBLN)
HCAT vs BBLN Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while BBLN trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas BBLN's P/E ratio is -0.04. In terms of profitability, HCAT's ROE is -1.00%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, HCAT is less volatile compared to BBLN. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check BBLN's competition here
HeartBeam, Inc. (NASDAQ: BEATW)
HCAT vs BEATW Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, BEATW has a market cap of 13.4M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while BEATW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas BEATW's P/E ratio is -0.04. In terms of profitability, HCAT's ROE is -1.00%, compared to BEATW's ROE of -10.34%. Regarding short-term risk, HCAT is less volatile compared to BEATW. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check BEATW's competition here
ETAO International Co., Ltd. (NASDAQ: ETAO)
HCAT vs ETAO Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while ETAO trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas ETAO's P/E ratio is -0.01. In terms of profitability, HCAT's ROE is -1.00%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, HCAT is less volatile compared to ETAO. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check ETAO's competition here
Bullfrog AI Holdings, Inc. Common Stock (NASDAQ: BFRG)
HCAT vs BFRG Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, BFRG has a market cap of 7.5M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while BFRG trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas BFRG's P/E ratio is -1.20. In terms of profitability, HCAT's ROE is -1.00%, compared to BFRG's ROE of -2.18%. Regarding short-term risk, HCAT is less volatile compared to BFRG. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check BFRG's competition here
Cue Health Inc. (NASDAQ: HLTH)
HCAT vs HLTH Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, HLTH has a market cap of 6.9M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while HLTH trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas HLTH's P/E ratio is -0.02. In terms of profitability, HCAT's ROE is -1.00%, compared to HLTH's ROE of -0.90%. Regarding short-term risk, HCAT is less volatile compared to HLTH. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check HLTH's competition here
Scienture Holdings, Inc. (NASDAQ: SCNX)
HCAT vs SCNX Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, SCNX has a market cap of 6.4M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while SCNX trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas SCNX's P/E ratio is -0.16. In terms of profitability, HCAT's ROE is -1.00%, compared to SCNX's ROE of -0.00%. Regarding short-term risk, HCAT is more volatile compared to SCNX. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check SCNX's competition here
UpHealth, Inc. (NYSE: UPH)
HCAT vs UPH Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while UPH trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas UPH's P/E ratio is -0.07. In terms of profitability, HCAT's ROE is -1.00%, compared to UPH's ROE of -1.05%. Regarding short-term risk, HCAT is less volatile compared to UPH. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check UPH's competition here
UpHealth, Inc. (NYSE: UPH-WT)
HCAT vs UPH-WT Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, UPH-WT has a market cap of 5.3M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while UPH-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas UPH-WT's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to UPH-WT's ROE of -1.05%. Regarding short-term risk, HCAT is less volatile compared to UPH-WT. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check UPH-WT's competition here
Mangoceuticals, Inc. (NASDAQ: MGRX)
HCAT vs MGRX Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, MGRX has a market cap of 4.2M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while MGRX trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas MGRX's P/E ratio is -0.31. In terms of profitability, HCAT's ROE is -1.00%, compared to MGRX's ROE of -1.21%. Regarding short-term risk, HCAT is less volatile compared to MGRX. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check MGRX's competition here
Pear Therapeutics, Inc. (NASDAQ: PEAR)
HCAT vs PEAR Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while PEAR trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas PEAR's P/E ratio is -0.08. In terms of profitability, HCAT's ROE is -1.00%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, HCAT is less volatile compared to PEAR. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check PEAR's competition here
Pear Therapeutics, Inc. (NASDAQ: PEARW)
HCAT vs PEARW Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while PEARW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas PEARW's P/E ratio is -0.00. In terms of profitability, HCAT's ROE is -1.00%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, HCAT is less volatile compared to PEARW. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check PEARW's competition here
Ontrak, Inc. (NASDAQ: OTRK)
HCAT vs OTRK Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while OTRK trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas OTRK's P/E ratio is -0.02. In terms of profitability, HCAT's ROE is -1.00%, compared to OTRK's ROE of -2.11%. Regarding short-term risk, HCAT is more volatile compared to OTRK. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check OTRK's competition here
VSee Health, Inc. (NASDAQ: VSEEW)
HCAT vs VSEEW Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, VSEEW has a market cap of 2.2M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while VSEEW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas VSEEW's P/E ratio is -0.06. In terms of profitability, HCAT's ROE is -1.00%, compared to VSEEW's ROE of -115.71%. Regarding short-term risk, HCAT is more volatile compared to VSEEW. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check VSEEW's competition here
Healthcare Triangle, Inc. (NASDAQ: HCTI)
HCAT vs HCTI Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, HCTI has a market cap of 2.1M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while HCTI trades at $1.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas HCTI's P/E ratio is -0.23. In terms of profitability, HCAT's ROE is -1.00%, compared to HCTI's ROE of -0.68%. Regarding short-term risk, HCAT is more volatile compared to HCTI. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check HCTI's competition here
CareMax, Inc. (NASDAQ: CMAX)
HCAT vs CMAX Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while CMAX trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas CMAX's P/E ratio is -0.00. In terms of profitability, HCAT's ROE is -1.00%, compared to CMAX's ROE of -2.01%. Regarding short-term risk, HCAT is more volatile compared to CMAX. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check CMAX's competition here
VSee Health, Inc. (NASDAQ: VSEE)
HCAT vs VSEE Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, VSEE has a market cap of 1.6M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while VSEE trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas VSEE's P/E ratio is -0.19. In terms of profitability, HCAT's ROE is -1.00%, compared to VSEE's ROE of -115.71%. Regarding short-term risk, HCAT is more volatile compared to VSEE. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check VSEE's competition here
Aclarion, Inc. (NASDAQ: ACON)
HCAT vs ACON Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, ACON has a market cap of 1.3M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while ACON trades at $2.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas ACON's P/E ratio is -0.24. In terms of profitability, HCAT's ROE is -1.00%, compared to ACON's ROE of -0.54%. Regarding short-term risk, HCAT is more volatile compared to ACON. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check ACON's competition here
MSP Recovery, Inc. (NASDAQ: LIFWZ)
HCAT vs LIFWZ Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while LIFWZ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to LIFWZ's ROE of +1.56%. Regarding short-term risk, HCAT is more volatile compared to LIFWZ. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check LIFWZ's competition here
EUDA Health Holdings Limited (NASDAQ: EUDAW)
HCAT vs EUDAW Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, EUDAW has a market cap of 926.3K. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while EUDAW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas EUDAW's P/E ratio is 0.03. In terms of profitability, HCAT's ROE is -1.00%, compared to EUDAW's ROE of +0.70%. Regarding short-term risk, HCAT is less volatile compared to EUDAW. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check EUDAW's competition here
SCWorx Corp. (NASDAQ: WORX)
HCAT vs WORX Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, WORX has a market cap of 693.4K. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while WORX trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas WORX's P/E ratio is -0.76. In terms of profitability, HCAT's ROE is -1.00%, compared to WORX's ROE of -0.65%. Regarding short-term risk, HCAT is more volatile compared to WORX. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check WORX's competition here
MSP Recovery, Inc. (NASDAQ: MSPRZ)
HCAT vs MSPRZ Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while MSPRZ trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to MSPRZ's ROE of +1.56%. Regarding short-term risk, HCAT is less volatile compared to MSPRZ. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check MSPRZ's competition here
Akerna Corp. (NASDAQ: KERN)
HCAT vs KERN Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while KERN trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas KERN's P/E ratio is -0.01. In terms of profitability, HCAT's ROE is -1.00%, compared to KERN's ROE of -0.17%. Regarding short-term risk, HCAT is less volatile compared to KERN. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check KERN's competition here
Akerna Corp. (NASDAQ: KERNW)
HCAT vs KERNW Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while KERNW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas KERNW's P/E ratio is -0.00. In terms of profitability, HCAT's ROE is -1.00%, compared to KERNW's ROE of -0.17%. Regarding short-term risk, HCAT is less volatile compared to KERNW. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check KERNW's competition here
MSP Recovery, Inc. (NASDAQ: LIFWW)
HCAT vs LIFWW Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while LIFWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas LIFWW's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to LIFWW's ROE of +1.56%. Regarding short-term risk, HCAT is more volatile compared to LIFWW. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check LIFWW's competition here
Zhongchao Inc. (NASDAQ: ZCMD)
HCAT vs ZCMD Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, ZCMD has a market cap of 58K. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while ZCMD trades at $1.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas ZCMD's P/E ratio is -0.06. In terms of profitability, HCAT's ROE is -1.00%, compared to ZCMD's ROE of -0.32%. Regarding short-term risk, HCAT is less volatile compared to ZCMD. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check ZCMD's competition here
CareMax, Inc. (NASDAQ: CMAXW)
HCAT vs CMAXW Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while CMAXW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas CMAXW's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, HCAT is more volatile compared to CMAXW. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check CMAXW's competition here
Aclarion, Inc. (NASDAQ: ACONW)
HCAT vs ACONW Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, ACONW has a market cap of 11.7K. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while ACONW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas ACONW's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to ACONW's ROE of -0.54%. Regarding short-term risk, HCAT is more volatile compared to ACONW. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check ACONW's competition here
CareCloud, Inc. (NASDAQ: MTBCO)
HCAT vs MTBCO Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, MTBCO has a market cap of 0. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while MTBCO trades at $25.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas MTBCO's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to MTBCO's ROE of +0.17%. Regarding short-term risk, HCAT is more volatile compared to MTBCO. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check MTBCO's competition here
MSP Recovery, Inc. (NASDAQ: MSPRV)
HCAT vs MSPRV Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, MSPRV has a market cap of 0. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while MSPRV trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas MSPRV's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to MSPRV's ROE of N/A. Regarding short-term risk, HCAT is less volatile compared to MSPRV. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check MSPRV's competition here
CareCloud, Inc. (NASDAQ: MTBCP)
HCAT vs MTBCP Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, MTBCP has a market cap of 0. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while MTBCP trades at $26.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas MTBCP's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to MTBCP's ROE of +0.17%. Regarding short-term risk, HCAT is more volatile compared to MTBCP. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check MTBCP's competition here
CareCloud, Inc. (NASDAQ: MTBC)
HCAT vs MTBC Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, MTBC has a market cap of 0. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while MTBC trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas MTBC's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to MTBC's ROE of +0.17%. Regarding short-term risk, HCAT is less volatile compared to MTBC. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check MTBC's competition here
Change Healthcare Inc. (NASDAQ: CHNG)
HCAT vs CHNG Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, CHNG has a market cap of 0. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while CHNG trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas CHNG's P/E ratio is -152.72. In terms of profitability, HCAT's ROE is -1.00%, compared to CHNG's ROE of -0.05%. Regarding short-term risk, HCAT is more volatile compared to CHNG. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check CHNG's competition here
Change Healthcare Inc. (NASDAQ: CHNGU)
HCAT vs CHNGU Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, CHNGU has a market cap of 0. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while CHNGU trades at $73.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas CHNGU's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to CHNGU's ROE of -0.05%. Regarding short-term risk, HCAT is more volatile compared to CHNGU. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check CHNGU's competition here
Convey Health Solutions Holdings, Inc. (NYSE: CNVY)
HCAT vs CNVY Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, CNVY has a market cap of 0. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while CNVY trades at $10.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas CNVY's P/E ratio is -71.50. In terms of profitability, HCAT's ROE is -1.00%, compared to CNVY's ROE of -0.02%. Regarding short-term risk, HCAT is more volatile compared to CNVY. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check CNVY's competition here
Nava Health MD, LLC (NASDAQ: NAVA)
HCAT vs NAVA Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, NAVA has a market cap of 0. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while NAVA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas NAVA's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to NAVA's ROE of +0.15%. Regarding short-term risk, HCAT is not fully comparable compared to NAVA. This indicates unavailable risk data in terms of short-term price fluctuations for HCAT.Check NAVA's competition here
Cerner Corporation (NASDAQ: CERN)
HCAT vs CERN Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, CERN has a market cap of 0. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while CERN trades at $94.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas CERN's P/E ratio is 55.84. In terms of profitability, HCAT's ROE is -1.00%, compared to CERN's ROE of +0.14%. Regarding short-term risk, HCAT is more volatile compared to CERN. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check CERN's competition here
Castlight Health, Inc. (NYSE: CSLT)
HCAT vs CSLT Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, CSLT has a market cap of 0. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while CSLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas CSLT's P/E ratio is -37.27. In terms of profitability, HCAT's ROE is -1.00%, compared to CSLT's ROE of -0.42%. Regarding short-term risk, HCAT is more volatile compared to CSLT. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check CSLT's competition here
NantHealth, Inc. (NASDAQ: NH)
HCAT vs NH Comparison July 2026
Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 166.3M. In comparison, NH has a market cap of 0. Regarding current trading prices, HCAT is priced at $2.25 on the NASDAQ, while NH trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 11.25, whereas NH's P/E ratio is -0.12. In terms of profitability, HCAT's ROE is -1.00%, compared to NH's ROE of +0.35%. Regarding short-term risk, HCAT is less volatile compared to NH. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check NH's competition here